Following the FDA's green light for a combo regimen of Sanofi’s Sarclisa in patients with newly diagnosed multiple myeloma ...

In the latest of several recent mpox vaccine supply deals, Bavarian Nordic plans to provide 1 million doses of its shot, ...

AstraZeneca and Daiichi Sankyo's Dato-DXd failed to improve survival in a breast cancer study. Gilead Sciences' Kite will bow ...

After more than a decade without any therapeutic advancements in chronic obstructive pulmonary disorder (COPD), people with ...

Shortly after winning full FDA approval for its rare kidney disease drug Filspari, San Diego’s Travere Therapeutics has run ...

At the recent World Conference on Lung Cancer and European Society for Medical Oncology | In this week's "The Top Line," ...

After nabbing a new FDA license for Rexulti in Alzheimer’s agitation last year, the drug’s marketing duo Lundbeck and Otsuka ...

Diagnosing multiple sclerosis (MS) can be an incredibly complex process for both patients and doctors. With symptoms that often overlap with, or mimic other conditions, making a definitive diagnosis ...

After decades of stagnation in the schizophrenia field, Bristol Myers Squibb’s $14 billion deal for Karuna Therapeutics has ...

Vaccine maker CSL Seqirus has lined up yet another contract with the U.S. | With a $121.4 million award from the U.S.

The days of broad stomach cancer labels for PD-1 inhibitors appear to be numbered.  | The days of broad stomach cancer labels ...

In June, at the American Society of Clinical Oncology (ASCO) conference in Chicago, when AstraZeneca discussed results from a ...